EUCTR2010-019288-13-GB进行中（未招募）不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 4,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patient is/has:
- •1. = 18 years of age at screening.
- •2. female who has had regular menstrual cycles monthly (22 to 32 days) for at least the last 3 cycles.
- •3. a history of migraine with or without aura for = 3 months and with = 2 migraine
- •attacks per month in the 2 months prior to screening (see Appendix 6.1 and ICHD II
- •Attachment for IHS migraine definitions).
- •4. headache during menstrual period in at least 2 out of last 3 cycles. Note: headache during menstrual period may occur within -2 days of menses onset to +3 days of menses cessation.
- •5. agrees to use (or have their partner use) a highly effective method of birth control
- •within the projected duration of the study. Complete details regarding contraceptive
- •requirements are specified in protocol Section 3.2.2.3.
- •6. understands the study procedures, alternative treatments available, and risks involved with the study, and voluntarily agrees to participate by giving written informed consent.
- •7. able to complete the paper patient headache diary.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient is/has:
- •1. basilar or hemiplegic migraine headache.
- •2. taken medication for acute headache attack on more than 15 days per month in any of the 3 months prior to screening.
- •3. taking migraine prophylactic medication where the prescribed daily dose has changed during the 4 weeks prior to screening.
- •4. pregnant (positive pregnancy test at pre-study), breast-feeding, or expecting to
- •conceive within the projected duration of the study.
- •5. clinical or laboratory evidence of uncontrolled hypertension (defined as SBP of = 160 mm Hg and/or DBP of = 100 mm Hg), uncontrolled diabetes, HIV disease, or
- •significant pulmonary, renal, hepatic, endocrine, or other systemic disease in the
- •opinion of the investigator.
- •6. myocardial infarction, unstable angina, coronary artery bypass surgery, or other
- •revascularization procedure, stroke, or transient ischemic attack within 3 months of
- •7. other confounding pain syndromes (i.e., condition requiring daily use of opioids),
- •psychiatric conditions such as uncontrolled major depression based on criteria such as DSM-IV, dementia or significant neurological disorders other than migraine.
- •8. history of neoplastic disease = 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- •9. history of gastric or small intestinal surgery (including gastric bypass surgery or
- •banding), or has a disease that causes malabsorption.
- •10. history or current evidence of any clinically significant disease that according to the investigator might confound the results of the study, complicate the interpretation of the study results, interfere with the patient’s participation for the full duration of the study, or pose an additional undue risk to the patient.
- •11. history of AST or ALT = 5 x upper limit of normal.
- •12. history of Gilbert’s syndrome, infectious hepatitis, or other significant hepatic disease in the opinion of the investigator. (e.g. any chronic hepatitis, cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis, or hereditary liver disease).
- •13. abnormal screening laboratory values as per the guidelines listed below or other
- •clinically significant, unexplained laboratory abnormality according to the investigator.
- •- AST >1.5 x upper limit of normal
- •- ALT > 1.5 x upper limit of normal
- •- Total bilirubin >1.5 x upper limit of normal
- •- Serum creatinine >2.0 x upper limit of normal
- •14. has taken any of the following systemic medications (oral/IV) in the time frame
- •Therapy Time Frame
- •Potent CYP3A4 inhibitors, including but not limited to: cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, nefazodone, HIV protease inhibitors
- •Potent CYP3A4 inducers, including but not limited to: rifampicin, rifabutin, carbamazepine, phenytoin, barbiturates (low-dose barbiturates permitted), systemic glucocorticoids (replacements and inhaled are permitted), nevirapine, efavirenz, pioglitazone, primidone Divalproex, Valproic acid 1 mo. prior to screening and
- •throughout the study period
- •15. history of hypersensitivity to more than two chemical classes of drugs, including
- •prescription and over-the-counter medications.
- •16. history (within the past 1 year) of drug or alcohol abuse.
- •17. consumes 3 or more alcoholic drinks per day. Note: 1 drink = 12 oz. can/bottle of
- •beer or 4 oz. of wine, or 1 oz. of liquor.
- •18. legally or mentally incapacitated.
- •19. donated blood produc
研究者
相似试验
已完成
3 期
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraineheadache10019231migraineNL-OMON34533Merck Sharp & Dohme (MSD)150
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine - MK0974-065MedDRA version: 12.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2010-019288-13-NLMerck, Sharp & Dohme B.V.4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMedDRA version: 12.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2010-019288-13-SEMSD4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMigraineEUCTR2010-019288-13-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,500
进行中（未招募）
不适用
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic MigraineMigraineEUCTR2010-019288-13-DKMerck Sharp & Dohme Corp.4,500